BioCentury
ARTICLE | Finance

Doubling down

1Q12 stocks: At least one biotech doubled value in every market cap group

April 2, 2012 7:00 AM UTC

Biotech investors lifted valuations across the board last quarter and made a handful of big bets that were driven by potential acquisitions, lawsuit settlements, strong earnings and positive clinical and regulatory news.

At least one biotech in each of BioCentury's five market cap segments doubled its valuation. That's no mean feat, especially for the big caps. In total, there were at least 20 opportunities for investors to double their money in a biotech company in 1Q12...